MX390374B - Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo] - Google Patents

Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]

Info

Publication number
MX390374B
MX390374B MX2019008118A MX2019008118A MX390374B MX 390374 B MX390374 B MX 390374B MX 2019008118 A MX2019008118 A MX 2019008118A MX 2019008118 A MX2019008118 A MX 2019008118A MX 390374 B MX390374 B MX 390374B
Authority
MX
Mexico
Prior art keywords
solid forms
thiazolo
pyrimidin
oxo
propyl
Prior art date
Application number
MX2019008118A
Other languages
English (en)
Other versions
MX2019008118A (es
Inventor
Frank Stowasser
Jing Xiong
Katja Grosse-Sender
Urs Schwitter
Xuemei Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019008118A publication Critical patent/MX2019008118A/es
Publication of MX390374B publication Critical patent/MX390374B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevas formas sólidas del compuesto (I), (ver formula) (I) 10 Comprendiendo el acetato de [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4- hidroxi-tetrahidrofuran-2-il]propilo] y composiciones farmacéuticas, las formas sólidas de las mismas descritas en la presente, que pueden utilizarse como un agonista de TLR7, o para el tratamiento o la profilaxis de una enfermedad viral en un paciente relacionado con una infección por VHB o una enfermedad causada por una infección por VHB.
MX2019008118A 2017-01-06 2018-01-04 Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo] MX390374B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017070439 2017-01-06
CN2017092183 2017-07-07
CN2017112151 2017-11-21
PCT/EP2018/050160 WO2018127526A2 (en) 2017-01-06 2018-01-04 New solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate

Publications (2)

Publication Number Publication Date
MX2019008118A MX2019008118A (es) 2019-09-13
MX390374B true MX390374B (es) 2025-03-11

Family

ID=61189399

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008118A MX390374B (es) 2017-01-06 2018-01-04 Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]
MX2022002331A MX2022002331A (es) 2017-01-06 2019-07-04 Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002331A MX2022002331A (es) 2017-01-06 2019-07-04 Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].

Country Status (10)

Country Link
US (1) US11230559B2 (es)
EP (1) EP3565819B1 (es)
JP (1) JP7125401B2 (es)
KR (2) KR102912761B1 (es)
CN (1) CN110167947B (es)
AU (2) AU2018205995B2 (es)
IL (3) IL307295A (es)
MX (2) MX390374B (es)
TW (2) TWI808069B (es)
WO (1) WO2018127526A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012421B2 (en) * 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) * 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP4081639A1 (en) * 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CA3190794A1 (en) 2020-08-05 2022-02-10 Soren Ottosen Oligonucleotide treatment of hepatitis b patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100016289A (ko) * 2007-05-08 2010-02-12 아스트라제네카 아베 면역-조정 특성의 이미다조퀴놀린
CA2963717C (en) 2014-12-08 2023-10-10 F. Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
WO2017211791A1 (en) * 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
EP3568400B1 (en) * 2017-01-06 2025-11-19 F. Hoffmann-La Roche AG Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Also Published As

Publication number Publication date
KR102783080B1 (ko) 2025-03-19
BR112019013911A2 (pt) 2020-02-04
JP7125401B2 (ja) 2022-08-24
IL307295A (en) 2023-11-01
TW202404604A (zh) 2024-02-01
AU2021277593A1 (en) 2021-12-23
US20200024288A1 (en) 2020-01-23
CN110167947B (zh) 2022-05-03
IL291855A (en) 2022-06-01
CA3048771A1 (en) 2018-07-12
AU2018205995A1 (en) 2019-06-06
MX2022002331A (es) 2022-04-06
IL267796A (en) 2019-09-26
KR102912761B1 (ko) 2026-01-15
IL291855B2 (en) 2024-03-01
EP3565819B1 (en) 2025-11-19
IL291855B1 (en) 2023-11-01
EP3565819C0 (en) 2025-11-19
CN110167947A (zh) 2019-08-23
EP3565819A2 (en) 2019-11-13
JP2020505325A (ja) 2020-02-20
AU2018205995B2 (en) 2021-09-23
KR20190099493A (ko) 2019-08-27
TWI808069B (zh) 2023-07-11
KR20230141899A (ko) 2023-10-10
WO2018127526A2 (en) 2018-07-12
MX2019008118A (es) 2019-09-13
US11230559B2 (en) 2022-01-25
TW201829420A (zh) 2018-08-16
WO2018127526A3 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12021550931A1 (en) New anthelmintic compounds
PH12020550065A1 (en) Hepatitis b antiviral agents
PH12017501061A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
MX2022002331A (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
PH12017501258B1 (en) Pyrazine compounds for the treatment of infectious diseases
PE20180501A1 (es) Lactamas biciclicas y metodos de uso de las mismas
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
EA201390198A1 (ru) Гетероциклическое соединение
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
PH12021552191A1 (en) Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
EA202090448A1 (ru) Дигидрооксадиазиноны
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX384745B (es) Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
MX2021011614A (es) Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX2019015480A (es) Preparacion medicinal combinada para tratar infecciones virales.